All Stories

  1. Genetic testing in pituitary adenomas: a Pituitary Society International Consensus Statement
  2. Genetics of Familial Acromegaly and Pituitary Gigantism
  3. A Young Woman with Paraneoplastic Cushing’s Syndrome Due to a Pulmonary Carcinoid
  4. Hypersomatotropism and Hypercortisolism Caused by a Plurihormonal Pituitary Adenoma in a Dog
  5. Experience evolves into evidence in the new MEN1 guidelines
  6. High prevalence of deleterious germline variants in cancer risk genes among subjects with young-onset, sporadic pituitary macroadenomas
  7. Tatton-Brown-Rahman syndrome: A new multiple endocrine neoplasia syndrome with intellectual disability?
  8. Expanding the phenotype of multiple endocrine neoplasia type 5 (MEN5): Pituitary gigantism, myelolipoma and familial pheochromocytoma due to a germline pathogenic MAX variant
  9. SIADH as an uncommon presentation of olfactory neuroblastoma: a case-based overview
  10. Chromatin conformation capture in the clinic: 4C-seq/HiC distinguishes pathogenic from neutral duplications at the GPR101 locus
  11. The Genetic Pathophysiology and Clinical Management of the TADopathy, X-Linked Acrogigantism
  12. Pituitary Acrogigantism: From the Past to the Future
  13. The Role of MCM9 in the Etiology of Sertoli Cell-Only Syndrome and Premature Ovarian Insufficiency
  14. Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion
  15. Bases moléculaires du gigantisme hypophysaire
  16. Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases
  17. Complicated Clinical Course in Incipient Gigantism Due to Treatment-resistant Aryl Hydrocarbon Receptor–Interacting Protein–mutated Pediatric Somatotropinoma
  18. Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism
  19. Comment on "Persistent remission of acromegaly in a patient with GH‐secreting pituitary adenoma: Effect of treatment with pasireotide long‐acting release and consequence of treatment withdrawal"
  20. Dutch founder SDHB exon 3 deletion in patients with pheochromocytoma-paraganglioma in South Africa
  21. Genetics of Pituitary Adenoma Syndromes
  22. A hard look at cardiac safety with dopamine agonists in endocrinology
  23. Differentiated thyroid carcinoma in sporadic and familial presentations of acromegaly: A case series
  24. GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11
  25. miR ‐34a is upregulated in AIP ‐ mutated somatotropinomas and promotes octreotide resistance
  26. The Epidemiology of Pituitary Adenomas
  27. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: GPR101, an orphan GPCR with roles in growth and pituitary tumorigenesis
  28. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The roles of AIP and GPR101 in familial isolated pituitary adenomas (FIPA)
  29. Pituitary Disease in AIP Mutation-Positive Familial Isolated Pituitary Adenoma (FIPA): A Kindred-Based Overview
  30. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
  31. Pancreatic Neuroendocrine Neoplasm Associated with a Familial MAX Deletion
  32. The role of AIP variants in pituitary adenomas and concomitant thyroid carcinomas in the Netherlands: a nationwide pathology registry (PALGA) study
  33. Clinical and Molecular Update on Genetic Causes of Pituitary Adenomas
  34. Acromegaly in the setting of Tatton-Brown-Rahman Syndrome
  35. Long-term remission of disseminated parathyroid cancer following immunotherapy
  36. GENETICS IN ENDOCRINOLOGY: Somatic and germline mutations in the pathogenesis of pituitary adenomas
  37. Compound heterozygous mutations in the luteinizing hormone receptor signal peptide causing 46,XY disorder of sex development
  38. Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma
  39. Shrinkage of pituitary adenomas with pasireotide
  40. AIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center
  41. AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
  42. Epidemiology and Management Challenges in Prolactinomas
  43. Genetic Testing in Pituitary Adenomas: What, How, and In Whom?
  44. The causes and consequences of pituitary gigantism
  45. Resistant Paediatric Somatotropinomas due to AIP Mutations: Role of Pegvisomant
  46. Cellular effects of AP102, a somatostatin analog with balanced affinities for the hSSTR2 and hSSTR5 receptors
  47. MAX intragenic deletions occur in patients with pheochromocytoma and pituitary adenoma
  48. Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats
  49. Acromegaly characteristics at diagnosis: the largest study to date.
  50. Adipsic diabetes insipidus revealing a bifocal intracranial germinoma
  51. AIP mutations and gigantism
  52. Overview of XLAG and how we discovered it
  53. Transdifferentiation of Neuroendocrine Cells
  54. Elucidating the molecular mechanisms underlying AIP dependent tumorigenesis
  55. GPR101 orphan receptor: a novel cause of growth hormone deregulation
  56. Comment on “Hypogonadotrophic hypogonadism due to a mutation in the luteinizing hormone β-subunit gene”
  57. Primary hypertrophic osteoarthropathy due to a novel SLCO2A1 mutation masquerading as acromegaly
  58. A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues
  59. New technology combined with a new disease used to explain an old case of gigantism
  60. Genetics of Pituitary Tumor Syndromes
  61. The role of AIP mutations in pituitary adenomas: 10 years on
  62. Erratum to: Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia
  63. Polymorphism or mutation? - The role of the R304Q missense AIP mutation in the predisposition to pituitary adenoma
  64. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia
  65. A region, common to all glycoprotein homones, essential for secretion
  66. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly
  67. Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening
  68. Characterization ofGPR101transcript structure and expression patterns
  69. Genetic predisposition to breast cancer occurring in a male-to-female transsexual patient
  70. Combined treatment with octreotide LAR and pegvisomant in patients with gigantism - acromegaly: clinical evaluation and genetic screening
  71. Expression of Peroxisome Proliferator-Activated Receptor alpha (PPARα) in somatotropinomas: Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) and in vitro effects of fenofibrate in GH3 cells
  72. MANAGEMENT OF ENDOCRINE DISEASE: Pituitary ‘incidentaloma’: neuroradiological assessment and differential diagnosis
  73. Genetic risk of breast cancer is important to consider in transexuals receiving hormone therapy
  74. Screening for GPR101 defects in pediatric pituitary corticotropinomas
  75. Mosaicism for X chromosome duplications including GPR101 cause X-LAG syndrome in sporadic males
  76. Gigantism, acromegaly and GPR101
  77. Bifocal intracranial germinoma presenting as adipsic diabetes insipidus
  78. Erratum to “Pituitary gigantism: Causes and clinical characteristics” [Ann. Endocrinol. (Paris) 76 (2015) 643–649]
  79. GPR101 Mutations are not a Frequent Cause of Congenital Isolated Growth Hormone Deficiency
  80. Functioning Pituitary Adenomas
  81. List of Contributors
  82. Growth hormone releasing hormone is abnormally elevated in patients with X-linked acrogigantism
  83. Pituitary gigantism: Causes and clinical characteristics
  84. Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome
  85. Étude moléculaire du gène AIP sur plus de 1400 individus atteints d’adénome hypophysaire
  86. Hyperparathyroïdie primaire familiale isolée – corrélation génotype-phénotype des mutations MEN1 ?
  87. Une forme compliquée d’hypercalcémie hypocalciurique familiale
  88. Causes and Characteristics of Pituitary Gigantism
  89. Pancreatitis in familial hypocalciuric hypercalcaemia
  90. Molecular analysis of miRNA expression profiles in AIP mutation positive somatotropinomas
  91. Recurrence of GH-secreting pituitary adenomas during puberty in children with germline AIP mutations: a clinical challenge
  92. Molecular and pathological determinants of somatostatin analogue resistance: somatotropinomas in AIP mutated and X-LAG syndrome patients
  93. The genetic causes of pituitary gigantism
  94. The clinical characteristics of X-linked acro-gigantism syndrome
  95. X-linked acro-gigantism (X-LAG): a new form of infant-onset pituitary gigantism
  96. Gigantism, Acromegaly, and GPR101 Mutations
  97. A novel inactivating mutation of the LH/chorionic gonadotrophin receptor with impaired membrane trafficking leading to Leydig cell hypoplasia type 1
  98. Familial Isolated Pituitary Adenomas (FIPA) and Mutations in the Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene
  99. X-linked acrogigantism syndrome: clinical profile and therapeutic responses
  100. Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences
  101. Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation
  102. McCune-Albright Syndrome: A Detailed Pathological and Genetic Analysis of Disease Effects in an Adult Patient
  103. Le cancer thyroïdien papillaire familial (FNMTC) : études cliniques et génétiques chez 8 familles
  104. Intérêt du signal T2 des adénomes hypophysaires à GH traités par analogues de la somatostatine – premiers résultats de l’étude IRMA#2
  105. Challenges and controversies in the treatment of prolactinomas
  106. A clinically novel AIP mutation in a patient with a very large, apparently sporadic somatotrope adenoma
  107. A bittersweet symphony
  108. Surgical management of pituitary adenomas
  109. The Third/Second Generation PTH Assay Ratio as a Marker for Parathyroid Carcinoma: Evaluation Using an Automated Platform
  110. Deletion of exons 1–3 of the MEN1 gene in a large Italian family causes the loss of menin expression
  111. Coexistence entre adénome hypophysaire et phéochromocytome – présentation de cas
  112. FIPA : étude clinique et génétique à l’Hôpital « King Edward Memorial », Bombay (Mumbai), Inde
  113. Le Gigantisme : les résultats d’une étude clinique et génétique internationale
  114. Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations
  115. Faculty Opinions recommendation of Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma.
  116. Receptor expression in craniopharyngiomas causing tumor growth in pregnancy: case report and review of the literature
  117. Characteristics of patients with pituitary gigantism: results of an international study
  118. Familial Isolated Pituitary Adenomas (FIPA) and the Pituitary Adenoma Predisposition due to Mutations in the Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene
  119. Young patients with pituitary adenomas should be assessed for MEN1 and AIP mutations
  120. Familial Pituitary Adenomas: An Overview
  121. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients
  122. Faculty Opinions recommendation of Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues.
  123. Faculty Opinions recommendation of Should aip gene screening be recommended in family members of FIPA patients with R16H variant?
  124. A study of the characteristics of cabergoline-resistant prolactinomas
  125. The Liege Acromegaly Survey (LAS): A new software tool for the study of acromegaly
  126. Clinical and genetic aspects of familial isolated pituitary adenomas
  127. Faculty Opinions recommendation of The endemic paraganglioma syndrome type 1: origin, spread, and clinical expression.
  128. Overview of genetic testing in patients with pituitary adenomas
  129. Clinical characterization of cabergoline resistant prolactinomas: A multicenter experience on 92 patients
  130. A prospective study of cardiac valvular status in patients treated with cabergoline for endocrine disease
  131. Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds
  132. Faculty Opinions recommendation of Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype.
  133. Faculty Opinions recommendation of Novel mutations in MEN1, CDKN1B and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in Spain.
  134. 36. A Tall Man with Hypogonadism
  135. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas
  136. Familial Pituitary Tumor Syndromes
  137. What to do with a pituitary incidentaloma?
  138. A Novel AIP Mutation Related to Familial Isolated Pituitary Adenomas (FIPA)
  139. Strategies for Screening and Management of Familial Isolated Pituitary Adenomas (FIPA): Our Experience on 17 Families in a Single Center in Brazil
  140. Impact of Germline AIP Mutations on Tumor Characteristics and Management in Young Acromegalic Patients: Results of an Age- and Tumor-Diameter-Matched Cohort Study
  141. Mutations of calcium-sensing receptor gene: two novel mutations and overview of impact on calcium homeostasis
  142. Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation
  143. Resistant prolactinomas
  144. Genetic susceptibility in pituitary adenomas: from pathogenesis to clinical implications
  145. Genetic Causes of Familial Pituitary Adenomas
  146. Familial pituitary adenomas
  147. Aggressive prolactinoma in a child related to germline mutation in the ARYL hydrocarbon receptor interacting protein (AIP) gene
  148. Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study
  149. The Ratio of Parathyroid Hormone as Measured by Third- and Second-Generation Assays as a Marker for Parathyroid Carcinoma
  150. Management of acromegaly
  151. The genetics of pituitary adenomas
  152. Hyperplasia-Adenoma Sequence in Pituitary Tumorigenesis Related to AIP Mutation.
  153. Prevalence of double pituitary adenomas in a surgical series: Clinical, histological and genetic features
  154. The role of germlineAIP,MEN1, PRKAR1A,CDKN1BandCDKN2Cmutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes
  155. Functioning Pituitary Adenomas
  156. Genetics of Cushing’s Syndrome
  157. Contributors
  158. Genetic Factors in the Development of Pituitary Adenomas
  159. Pituitary adenomas in young patients: when should we consider a genetic predisposition?
  160. The epidemiology and genetics of pituitary adenomas
  161. De la génétique des adénomes hypophysaires familiaux
  162. Aggressive pituitary adenomas occurring in young patients in a large Polynesian kindred with a germline R271W mutation in the AIP gene
  163. Mutaciones de AIP en adenomas hipofisarios familiares y esporádicos: experiencia local y revisión de la literatura
  164. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly
  165. Familial pituitary adenomas
  166. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications
  167. Genetic, Molecular and Clinical Features of Familial Isolated Pituitary Adenomas
  168. Adénomes hypophysaires familiaux
  169. Update on Familial Pituitary Tumors: from Multiple Endocrine Neoplasia Type 1 to Familial Isolated Pituitary Adenoma
  170. Testicular Effects of Isolated Luteinizing Hormone Deficiency and Reversal by Long-Term Human Chorionic Gonadotropin Treatment
  171. Central Nervous System-Acting Drugs Influencing Hypothalamic-Pituitary-Adrenal Axis Function
  172. UPDATE ON THE TREATMENT OF PITUITARY ADENOMAS: FAMILIAL AND GENETIC CONSIDERATIONS
  173. Toll‐like receptor‐4 is expressed in meningiomas and mediates the antiproliferative action of paclitaxel
  174. Cabergoline and the risk of valvular lesions in endocrine disease.
  175. Absence of hypogonadism in a male patient with a giant prolactinoma: A clinical paradox
  176. Current and future perspectives on recombinant growth hormone for the treatment of obesity
  177. Pseudomalabsorption of thyroid hormones: case report and review of the literature
  178. Characteristics of familial isolated pituitary adenomas
  179. Vitex agnus castus might enrich the pharmacological armamentarium for medical treatment of prolactinoma
  180. The clinical, pathological, and genetic features of familial isolated pituitary adenomas
  181. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene
  182. Mutations in theAryl Hydrocarbon Receptor Interacting ProteinGene Are Not Highly Prevalent among Subjects with Sporadic Pituitary Adenomas
  183. Aryl Hydrocarbon Receptor-Interacting Protein Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families
  184. The Epidemiology and Management of Pituitary Incidentalomas
  185. High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
  186. P1-046 - The liege acromegaly survey
  187. CO05 - Identification d’une famille porteuse d’une nouvelle mutation bêta-LH accompagnée d’hypogonadisme
  188. P2-085 - Endocrine abnormalities in MC Cune-Albright syndrome
  189. P1-044 - Les patients acromégales sont-ils mal pris en charge ? de la mauvaise utilisation des bases de données
  190. The original clinical description of familial isolated pituitary adenomas (FIPA)
  191. Serum levels of soluble CD163 correlate with the inflammatory process in coeliac disease
  192. Desloratadine for allergic rhinitis
  193. Diagnostic characteristics and therapeutic responses in acromegaly: The liege acromegaly survey
  194. Does the nadir growth-hormone level predict response to somatostatin-analogue therapy?
  195. Somatostatin Analogs in the Gastrointestinal Tract
  196. Predictors and rates of treatment-resistant tumor growth in acromegaly
  197. Acromegaly
  198. Clinical and Genetic Features of Familial Pituitary Adenomas
  199. Treatment of Pituitary Tumors: Somatostatin
  200. The Epidemiology of Prolactinomas
  201. Cytokine Dysregulation, Inflammation and Well-Being
  202. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs
  203. Desloratadine prevents compound 48/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique
  204. Hypogonadism in a Patient with a Mutation in the Luteinizing Hormone Beta-Subunit Gene
  205. P018 - Une approche de la vraie prévalence des tumeurs hypophysaires
  206. CO10 - La réduction chirurgicale de la masse tumorale des adenomas hypophysaires améliore le contrôle médical de l’acromégalie par les analogues de la somatostatine
  207. Oral vitamin C reduces the injury to skeletal muscle caused by compartment syndrome
  208. Hormonal and Biochemical Normalization and Tumor Shrinkage Induced by Anti-Parathyroid Hormone Immunotherapy in a Patient with Metastatic Parathyroid Carcinoma
  209. Lanreotide Autogel?? for Acromegaly
  210. Gonadotropin-Secreting Tumors
  211. Oral vitamin C attenuates acute ischaemia-reperfusion injury in skeletal muscle
  212. Alcoholic ketoacidosis presenting as diabetic ketoacidosis
  213. Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines☆☆☆★
  214. Pathologie inflammatoire de ľhypophyse et grossesse